Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 13, No. 4, 2004
Issue release date: July – August
Section title: Original Paper

Open Access Gateway

Med Princ Pract 2004;13:185–190

Selenium in the Treatment of Head and Neck Lymphedema

Bruns F.a,b,f · Büntzel J.c,f · Mücke R.d,f · Schönekaes K.f · Kisters K.e,f · Micke O.b,f
aDepartment of Radiotherapy, Medical School Hannover, Hannover, bDepartment of Radiotherapy, Münster University Hospital, Münster, cDepartment of Otolaryngology, Community Hospital Nordhausen, Nordhausen, dDepartment of Radiotherapy, Community Hospital Weiden, Weiden, and eDepartment of Internal Medicine, St. Anna Hospital Herne, Herne, Germany; fGerman Working Group Trace Elements and Electrolytes in Radiation Oncology (AKTE)
email Corresponding Author

Dr. Oliver Micke

Klinik und Poliklinik für Strahlentherapie-Radioonkologie

Universitätsklinikum Münster, Albert-Schweitzer-Strasse 33

DE–48129 Münster (Germany)

Tel. +49 251 8347839, Fax +49 251 8347355, E-Mail omicke@trace-elements.de

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Objective: To investigate the impact of selenium in the treatment of lymphedema of the head and neck region after radiotherapy alone or in combination with surgery. Subjects and Materials: Between June 1996 and June 2001 a total of 36 cancer patients (29 male, 7 female; median age 61 years) were treated with selenium for persistent, extensive or progressive lymphedema of the head and neck region. Twenty had interstitial endolaryngeal edema associated with stridor and dyspnea. All patients received 350 µg/m2 body surface sodium selenite medication p.o. daily (total dose 50 µg per day) for a period of 4–6 weeks after radiotherapy. The optimal effect of the selenium treatment was assessed after 4 weeks of therapy using the Miller score system. A visual analogue scale on a scale of 0–10 was used to assess the patient’s quality of life prior to and after selenium. Results: 75% of the patients had an improvement of the Miller score of one stage or more. The self-assessment of quality of life using the visual analogue scale improved significantly after selenium treatment with a reduction of 4.4 points (p < 0.05). Of the 20 patients with endolaryngeal edema tracheostomy was not necessary in 13 patients (65%), but 5 and 2 received a temporary or permanent tracheostomy, respectively. No episode of erysipelas was observed in all study patients. Conclusion: Our results suggest a short positive effect of sodium selenite on secondary head and neck lymphedema caused by radiotherapy alone or in combination with surgery.

© 2004 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: August 03, 2003
Published online: June 10, 2004
Issue release date: July – August

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 3

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: http://www.karger.com/MPP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.